| Document |
Document Title |
|
WO/2024/094237A1 |
Novel derivatives of human insulin are described that have binding affinities for the IGF-1 receptor surprisingly comparable to human IGF-1, while having higher affinities for both isoforms of the insulin receptor than human insulin. The...
|
|
WO/2024/097713A1 |
In one embodiment, the present disclosure provides hypoallergenic peanut allergens Ara h 6 variants wherein at least one epitope recognized by anti-Ara h 6 antibodies has been modified, thereby having reduced or abolished antibody bindin...
|
|
WO/2024/097901A1 |
. Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Also provided are derivative cells having stable and functional...
|
|
WO/2024/097904A1 |
This disclosure provides, among other things, an engineered immunosuppressive (e.g., CD4+) T cell comprising a molecular circuit comprising the following components: (a) a central nervous system (CNS)-specific binding-triggered transcrip...
|
|
WO/2024/095149A1 |
The present invention relates to hydrolysed collagen products or collagen hydrolysates, a process for their preparation and their uses as anti-inflammatory and/or analgesic active ingredients for topical applications such as for example ...
|
|
WO/2024/097637A1 |
Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a human BRAFV600E amino acid sequence. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression ...
|
|
WO/2024/092740A1 |
Provided is a method for detecting intercellular interaction. The method comprises: (1) preparing a first cell expressing a TCR activation response element and a reporter molecule, the first cell expressing a TCR; (2) co-incubating an an...
|
|
WO/2024/097655A1 |
Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated amino acid sequence encoded by mutated CDKN2A. The TCRs may recognize mutated CDKN2A peptide presented by an HLA-A molecu...
|
|
WO/2024/095006A1 |
The present invention relates to a therapeutic agent comprising an autoregulation element, preferably wherein the therapeutic agent is an antigen binding protein. Methods of treatment comprising use of said agent are also disclosed.
|
|
WO/2024/097800A1 |
Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Also provided are derivative cells having stable and functional g...
|
|
WO/2024/097441A1 |
The present application provides methods of treating a complement-mediated disease in a human individual, comprising administering to the individual an effective amount of a fusion protein comprising i) an antibody moiety that specifical...
|
|
WO/2024/097276A1 |
This document relates to methods and materials involved in treating cancer. For example, methods and materials for using chimeric antigen receptor (CAR) T cells having reduced levels of an interleukin (IL) 4 polypeptide, having reduced l...
|
|
WO/2024/097737A1 |
The present disclosure relates to compositions and methods for treating blood vessel epicardial substance (BVES) protein-related disorders.
|
|
WO/2024/094481A1 |
The present invention concerns a microorganism comprising at least one gene coding for a protein having the function of a L-arginine:glycine amidinotransferase and having an increased activity of a transmembrane exporter protein and to a...
|
|
WO/2024/097796A1 |
The present application provides methods of treating a complement-mediated disease in a human individual, comprising administering to the individual an effective amount of a fusion protein comprising i) an antibody moiety that specifical...
|
|
WO/2024/094483A1 |
The present invention concerns a microorganism comprising at least one gene coding for a protein having the function of a L-arginine:glycine amidinotransferase and having an increased activity of a rt protein belonging to the Amino Acid-...
|
|
WO/2024/092330A1 |
The present invention relates to nucleotide sequences that encode new truncated chimeric insecticidal proteins that exhibit inhibitory activity on lepidopterans. Particular embodiments provide compositions and plants, parts of parts, and...
|
|
WO/2024/094328A1 |
The present invention relates to an isolated polypeptide, or a functional fragment thereof, having at least 85% sequence identity to SEQ ID NO: 12, comprising an amino acid substitution at position C113, preferably C113A.5
|
|
WO/2024/095289A1 |
The present invention relates to Bio-pharmaceuticals. Specifically, the present invention relates to mutated Factor H binding proteins (fHbp) of N. meningitidis serogroup B. Further, the present invention relates to compositions of facto...
|
|
WO/2024/093042A1 |
Provided are an anti-BSA rabbit monoclonal antibody and use thereof, which belong to the technical field of antibodies. The anti-BSA rabbit monoclonal antibody or an antigen-binding portion thereof specifically binds to BSA. The monoclon...
|
|
WO/2024/093915A1 |
Provided are a protein comprising an amino acid sequence capable of binding to a substrate GPRP peptide fragment, a fibrinogen like protein 1 (FGL1) comprising the amino acid sequence, and a fibrinogen domain (FD) thereof, and an individ...
|
|
WO/2024/098037A1 |
The present disclosure provides chimeric receptor constructs comprising a CD3e extracellular domain and engineered NK and T cells expressing such receptors and methods of making and using same for the treatment of cancer and other diseas...
|
|
WO/2024/096592A1 |
The present invention relates to an anti-mesothelin chimeric antigen receptor that specifically binds to mesothelin with increased affinity for methothelin. The anti-mesothelin chimeric antigen receptor according to an aspect exhibits sp...
|
|
WO/2024/096378A1 |
The present invention relates to a pretreatment method for isolating a TGF-β3 protein from E. coli and purifying same with high efficiency and high purity, and a TGF-β3 protein purification method comprising the pretreatment method. Th...
|
|
WO/2024/096545A1 |
The present application relates to a microorganism producing purine nucleotides and a method for producing purine nucleotides using same.
|
|
WO/2024/098071A1 |
This disclosure relates to the once weekly dosing regimen of a dual GLP-1R and GCGR agonist, formulations, and methods of using the same for treatment of cardiovascular disease/disorder and/or reducing risk factors thereof by inducing re...
|
|
WO/2024/096522A1 |
The present invention relates to an antibody binding to CD22, and a bispecific antibody, a chimeric antigen receptor and an antibody-drug conjugate comprising same, and use thereof. According to one embodiment, an effective cancer treatm...
|
|
WO/2024/096038A1 |
The present invention addresses the problem of providing a method for producing active HGF in an industrially advantageous manner, by expressing HGF α chain and HGF β chain in the same host cell. The present disclosure provides a met...
|
|
WO/2024/094002A1 |
The present invention relates to a fructose diphosphate optical probe. Specifically, provided in the present invention is a fructose diphosphate optical probe, which comprises a fructose-1,6-diphosphate sensitive polypeptide and an optic...
|
|
WO/2024/094119A1 |
The present invention relates to a fusion protein, which comprises an anti-T cell surface molecular antibody, interleukin 2, and immunoglobulin Fc. The fusion protein is a heterodimer or a homodimer. The present invention further relates...
|
|
WO/2024/094881A1 |
The present disclosure provides methods for eliciting an immune response against respiratory syncytial virus (RSV) in a subject. The present disclosure also provides methods for preventing an RSV infection or reducing one or more symptom...
|
|
WO/2024/092769A1 |
Provided is a fusion polypeptide comprising a carrier protein and a polypeptide of interest, wherein the polypeptide of interest is fused to a terminus of the carrier protein or inserted into the carrier protein, and wherein the carrier ...
|
|
WO/2024/097911A1 |
Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Also provided are derivative cells having stable and functional g...
|
|
WO/2024/094578A1 |
The present invention is directed to seedless fruit producing melon. The present invention also comprises methods for production of said plants and methods for producing seedless melon. Plants and plant parts of the invention comprise at...
|
|
WO/2024/096742A1 |
The invention is in the field of medical treatment, and relates to a method for treating SARS-CoV-2 infections. In particular, the present invention relates to methods for prophylactic and/or therapeutic treatment of betacoronavirus infe...
|
|
WO/2024/094556A1 |
The present invention discloses a method for generating a plurality of biocompatible fibroin fibres (6) generated from the turbulent mixing produced in the inner mixing region of a nebulizer, among a dope stream comprising a dope solutio...
|
|
WO/2024/096677A1 |
The present invention relates to a peptide library derived from the vast TIR domains present across various biological species, a construction method therefor, and a novel peptide, screened from this library, which is involved in the TLR...
|
|
WO/2024/094597A1 |
The invention relates to methods for the preparation of method of preparation of Tau aggregates, including fibrils, fibrillar species, soluble and insoluble oligomeric species, new Tau aggregates and uses thereof. The invention further r...
|
|
WO/2024/097763A1 |
The present application is directed to multiplex intein-based methods and compositions for the generation engineered cells expressing modular polypeptides, for example CARs and CCRs.
|
|
WO/2024/097652A2 |
The present disclosure is related to T cell receptors that recognize or bind to Kras G12V mutant proteins or peptides thereof, genetically engineered cells based on such T cell receptors, and cell-based therapies.
|
|
WO/2024/097871A1 |
The invention relates to antigenic polypeptides derived from a naturally occurring R. microplus protein, and nucleic acids encoding such polypeptides. The polypeptides elicit an immune response which, in turn, produces detrimental effect...
|
|
WO/2024/097941A1 |
A method of treating malignancy in a subject in need thereof is provided. The method includes administering a therapeutically effective amount of a compound that increases the level of one or more of piR_017723, piR_23656, or piR_016745,...
|
|
WO/2024/095177A1 |
The present disclosure provides a manganese bifunctional chelating agent conjugation platform for targeted MR imaging. The platform includes an MRI-active manganese porphyrin (MnP) compound connected to a linker which in turn is connecte...
|
|
WO/2024/098054A1 |
Compositions and methods for depleting B cells and/or eliminating neutralizing antibodies, particularly for AA V gene therapy administration, are disclosed. Neutralizing alloantibodies (NAbs) to adeno-associated virus (AAV) occur both na...
|
|
WO/2024/096648A1 |
The present invention relates to a novel recombinant PCV2d antigen and a use thereof, wherein an ORF2 sequence of the existing PCV2 is subjected to codon and vector optimization so as for the sequence to be expressed in insect cells, and...
|
|
WO/2024/094755A1 |
Provided are engineered heterodimeric immunocytokines, including fusions of IL4 and IL10, IL4 and IL13, or IL10 and IL13 to the heavy chains of an Fc fragment. In addition, fusion polypeptides are provided that comprise an engineered mon...
|
|
WO/2024/097976A1 |
Compositions and methods of inducing an immune response in a subject having RSV comprising administering a pharmaceutical composition comprising a prophylactic vaccine against RSV infection, wherein the vaccine comprises a live recombina...
|
|
WO/2024/097788A1 |
Described herein are Campylobacter jejuni β1–4GalNAcT (CjCgtA) variants comprising a polypeptide having at least 80% identity to the amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 2. Also described herein are Campylobacte...
|
|
WO/2024/094992A1 |
Disclosed is an aminopeptidase (having a protease associated (PA) domain and a (catalytic) protease domain (PD)) that is self-regulated whereby the C-terminal portion of the aminopeptidase sequence binds in a cleft between the PA domain ...
|
|
WO/2024/097918A1 |
This disclosure provides methods of treating cancers, such as lung cancer, esophageal cancer, renal cancer, and head and neck cancer, with NKG2D fusion proteins, NKG2D fusion proteins for use in methods of treating a subject having cance...
|
